Latest Conference Articles

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.

Questions arise around equity and revenue challenges.

Food is medicine is a framework of policy and behavioral interventions, improving population health through access to healthy foods to increase food and nutrition security.

Niki Shah Vice President of Impact Innovation and Activation at McKesson, discusses efforts to advance health equity and access through community pharmacy initiatives.

W. Timothy Garvey expressed concern over limited access to effective obesity medications like Ozempic due to shortages and high costs, urging stakeholders to work together on developing solutions.

Semaglutide significantly improved heart failure symptoms and quality of life through weight loss and direct effects on heart tissue.

Adding a community health worker can improve the overall health equity for your patients.

Potential concerns surrounding GLP-include pancreatitis, pancreatic cancer, colorectal cancer, suicide and other phycological effects, and thyroid cancer.

There are approximately 98 million individuals have prediabetes, but approximately only 15 million actually know they have prediabetes.

Semaglutide was found to have effects on glycemia, inflammation, and heart failure outcomes in sub analyses.

Based on these results, tirzepatide could be first medication approved for treatment of obstructive sleep apnea in patients with obesity.

Managing these treatments involves many considerations, including glycemic control and nutrition, among others.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Presenters at the American Diabetes Association 84th Scientific Sessions analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.

The study shows that tirzepatide significantly improves secondary outcomes in patients with sleep apnea.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

With improved technology and innovations for diabetes, it is essential for health care providers and health agencies to collaborate to combat rising rates of diabetes.

Niki Shah Vice President of Impact Innovation and Activation at McKesson, previews the 2024 McKesson ideaShare conference.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo emphasizes the importance of the pharmacist’s role in diabetes care and his hopes for the future of care.

Fostering communication and shared terminology is key.

Pharmacy Times will be at McKesson ideaShare 2024 Conference in New Orleans, Louisiana from June 23 to June 26, 2024.

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Pharmacy Times will be at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida from June 21 to June 24, 2024.

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.